Symptoms of late-onset NMOSD, occurring in patients over 50, may look like those of a stroke and can delay proper diagnosis and treatment.| Neuromyelitis News
A new predictive model to identify neuromyelitis optica spectrum disorder patients at a higher risk of relapse was found accurate in a study.| Neuromyelitis News
Nearly all clinicians (88%) in a U.S. survey have prescribed approved NMOSD treatments for their patients with anti-AQP4 antibodies.| Neuromyelitis News
Uplizna is an FDA-approved treatment for adults with neuromyletis optica spectrum disorder who test positive for AQP4-IgG antibodies.| Neuromyelitis News
Depression, anxiety, and sleep disturbances are common among patients with neuromyelitis optica spectrum disorder, a new meta-analysis shows.| Neuromyelitis News
In her debut column for "The Beginner's Guide to Walking," Jennifer van Amerom describes the role music played in her NMOSD diagnosis.| Neuromyelitis News
Marisa Wexler is a senior science writer for Neuromyelitis News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Rituximab was more efficient at preventing relapses than oral immunosuppressive therapies in a racially diverse group of people with NMOSD.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
Immunosuppressive therapy is safe and was found to significantly reduce relapses in elderly patients with late-onset NMOSD, per a study.| Neuromyelitis News
